IL122980A0 - Traf inhibitors - Google Patents

Traf inhibitors

Info

Publication number
IL122980A0
IL122980A0 IL12298096A IL12298096A IL122980A0 IL 122980 A0 IL122980 A0 IL 122980A0 IL 12298096 A IL12298096 A IL 12298096A IL 12298096 A IL12298096 A IL 12298096A IL 122980 A0 IL122980 A0 IL 122980A0
Authority
IL
Israel
Prior art keywords
traf
inhibitors
trafs
pharmaceuticals
nucleic acid
Prior art date
Application number
IL12298096A
Other languages
English (en)
Original Assignee
Genentech Inc
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Tularik Inc filed Critical Genentech Inc
Publication of IL122980A0 publication Critical patent/IL122980A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL12298096A 1995-08-17 1996-08-14 Traf inhibitors IL122980A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US238295P 1995-08-17 1995-08-17
PCT/US1996/013129 WO1997007134A1 (fr) 1995-08-17 1996-08-14 Inhibiteurs du facteur associe au recepteur du facteur de necrose tumorale

Publications (1)

Publication Number Publication Date
IL122980A0 true IL122980A0 (en) 1998-08-16

Family

ID=21700513

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12298096A IL122980A0 (en) 1995-08-17 1996-08-14 Traf inhibitors

Country Status (13)

Country Link
US (6) US5789550A (fr)
EP (2) EP0845005B1 (fr)
JP (2) JP4382878B2 (fr)
AT (1) ATE291585T1 (fr)
AU (1) AU709535B2 (fr)
CA (1) CA2227174A1 (fr)
DE (1) DE69634512T2 (fr)
DK (1) DK0845005T3 (fr)
ES (1) ES2239334T3 (fr)
IL (1) IL122980A0 (fr)
NZ (1) NZ315514A (fr)
WO (1) WO1997007134A1 (fr)
ZA (1) ZA966663B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966663B (en) * 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
PT951551E (pt) 1996-12-23 2008-10-28 Immunex Corp Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6723517B1 (en) 1998-06-02 2004-04-20 Minerva Biotechnologies Corporation Use of self-assembled monolayers to probe the structure of a target molecule
AU4567299A (en) * 1998-06-22 2000-01-10 Feshchenko, Elena A. C-cbl suppression of neoplastic transformation
JP2003510049A (ja) * 1999-09-23 2003-03-18 ライジェル・ファーマシューティカルズ・インコーポレイテッド Ｔｒａｆ４関連細胞周期タンパク質、組成物および使用法
WO2002064786A1 (fr) * 2001-02-15 2002-08-22 Mochida Pharmaceutical Co., Ltd. Nouveau gene tcif
US20050100547A1 (en) * 2001-06-07 2005-05-12 Pu Xia Etal Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
CA2451955C (fr) 2001-06-26 2015-09-29 Abgenix, Inc. Anticorps opgl
US20030083304A1 (en) * 2001-10-09 2003-05-01 Smart Robert C. CCAAT/enhancer binding protein-beta (C/EBPbeta) is a molecular target for cancer treatment
IL145918A0 (en) * 2001-10-14 2002-07-25 Ares Trading Sa Method and kit for monitoring recruitment of proteins to the intracellular domain of a receptor in intact cells
AU2003258036A1 (en) * 2002-08-01 2004-02-23 Wyeth Methods and reagents relating to inflammation and apoptosis
RU2009141592A (ru) * 2007-04-11 2011-05-20 Алькон Рисерч, Лтд. (Us) ПРИМЕНЕНИЕ ИНГИБИТОРА TNFα В СОЧЕТАНИИ С АНТИГИСТАМИННЫМ СРЕДСТВОМ ДЛЯ ЛЕЧЕНИЯ АЛЛЕРГИЧЕСКОГО РИНИТА И АЛЛЕРГИЧЕСКОГО КОНЪЮНКТИВИТА
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
WO2009143141A1 (fr) * 2008-05-19 2009-11-26 Case Western Reserve University Procédé de traitement de maladies à médiation par cd40
US12319726B2 (en) 2008-05-19 2025-06-03 Case Western Reserve University Method for treating CD40-mediated diseases
US10669345B2 (en) * 2008-05-19 2020-06-02 Case Western Reserve University Method for treating CD40-mediated diseases
NZ594155A (en) 2009-01-21 2013-02-22 Vertex Pharma Methods for amplifying hepatitis c virus nucleic acids
RU2012117141A (ru) * 2009-10-01 2013-11-10 Алькон Рисерч, Лтд. Композиции олопатадина и способы их применения
US12522633B2 (en) 2020-04-02 2026-01-13 Case Western Reserve University Compositions and methods for treating CD40-mediated diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3613167A1 (de) * 1986-04-18 1987-10-29 Basf Ag Verwendung von tnf zur herstellung von arzneimitteln
US5108901A (en) 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE59010908D1 (de) * 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5318890A (en) 1991-05-06 1994-06-07 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
WO1996020723A1 (fr) * 1994-12-30 1996-07-11 Brigham & Women's Hospital Regulation de signaux induits par traf
ZA966663B (en) * 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.

Also Published As

Publication number Publication date
ZA966663B (en) 1998-02-06
CA2227174A1 (fr) 1997-02-27
US20040087774A1 (en) 2004-05-06
EP0845005A1 (fr) 1998-06-03
JP2009065981A (ja) 2009-04-02
US6294348B1 (en) 2001-09-25
NZ315514A (en) 1998-12-23
EP1568708A3 (fr) 2005-10-12
US6060303A (en) 2000-05-09
JPH11511967A (ja) 1999-10-19
WO1997007134A1 (fr) 1997-02-27
AU6723796A (en) 1997-03-12
DE69634512D1 (de) 2005-04-28
US6004553A (en) 1999-12-21
AU709535B2 (en) 1999-09-02
US6063585A (en) 2000-05-16
EP1568708A2 (fr) 2005-08-31
US5789550A (en) 1998-08-04
DE69634512T2 (de) 2006-02-09
JP4382878B2 (ja) 2009-12-16
ATE291585T1 (de) 2005-04-15
MX9800995A (es) 1998-10-31
EP0845005B1 (fr) 2005-03-23
ES2239334T3 (es) 2005-09-16
DK0845005T3 (da) 2005-08-01

Similar Documents

Publication Publication Date Title
ZA966663B (en) Traf Inhibitors.
HU9600692D0 (en) Human metabotropic glutamate receptor subtypes (hmr4, hmr6, hmr7) and related dna compounds
IL112873A (en) Rapamycin-fkbp12 binding proteins, their isolation and their use
PL313256A1 (en) Protocadherine proteins and their applications
GR3032635T3 (en) Drug binding protein
AU1689297A (en) Chemokine receptors 88-2B(CKR-3) and 88C and their antibodies
EP0832973A3 (fr) Protéine de liaison de GTP
WO1998030694A3 (fr) RECEPTEURS 6α ET 6β DU FACTEUR DE NECROSE TUMORALE
DK0962531T3 (da) Interferon-gammaproduktion inducerende isoleret polypeptidfragment og et isolaret DNA-fragment der koder for dette polypeptid
EP0731636A4 (fr) Nouvelles proteines modulant l'apoptose, adn codant pour ces proteines, et leur mode d'utilisation
DE69535274D1 (de) Verwendung eines menschlichen interleukin-11 rezeptors
MXPA01006006A (es) Cadena receptora de citocina.
GR3036782T3 (en) Proteases capable of shedding the soluble TNF-receptor and TNF-R derived peptides and antibodies against the proteases inhibiting the shedding.
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
DE69504795D1 (de) Methoden zur synthese und reinigung von peptiden
DE69328060D1 (de) Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
EP0911409A3 (fr) Deformylase
WO1998002557A3 (fr) Fnt-alpha convertase mammalienne
IL139272A0 (en) New peptide fragments for protein purification
WO2002059149A3 (fr) Proteines pro-apoptotiques et molecules d'adn les codant
WO2001021794A3 (fr) Polypeptides associant smad
MX9700255A (es) Metodo para identificar acidos nucleicos que codifican las proteinas activadoras del promotor c-fos.
WO2002006309A3 (fr) Peptides signaux d'exportation nucleaire (nes), proteines de fusion qui les contiennent, ainsi que leur utilisation